Kintara Therapeutics(KTRA) - 2021 Q4 - Annual Report

Mergers and Acquisitions - The company completed a merger with Adgero Biopharmaceuticals Holdings, resulting in the conversion of each share of Adgero common stock into 1.5740 shares of the company's common stock[13]. Fundraising and Financials - The company raised approximately $15 million in gross proceeds by issuing 7,200,000 shares of common stock and warrants, which will fund the Phase 2/3 clinical study for GBM[19]. - The company plans to evaluate options for strategic direction, including raising additional capital and potential acquisitions[35]. - The company is obligated to pay milestone payments of $300,000 and $700,000 upon certain conditions, with potential payments in common stock based on recent financing[156]. - A royalty fee of 6% on net sales is owed to St. Cloud and Steven Rychnovsky, PhD, with specific distributions of 4.8% and 1.2% respectively[157]. Clinical Trials and Studies - Positive topline data was reported for the adjuvant arm of the Phase 2 clinical study of VAL-083, showing its potential as a treatment for GBM patients[19]. - The company activated 26 clinical sites in the U.S. for the GBM AGILE registration study, which evaluates multiple therapies for newly-diagnosed and recurrent GBM[19]. - VAL-083 is currently the only therapeutic agent being evaluated in all three GBM patient subtypes in the GBM AGILE study[29]. - The GBM AGILE Study plans to enroll 150-200 patients in the Kintara arm across over 40 sites in the U.S. and Canada, with potential expansion to 65 clinical study centers worldwide[42]. - In a Phase 2 study, VAL-083 demonstrated a median progression-free survival (PFS) of 9.3 months for 29 patients, compared to historical PFS of 5.3 months and 6.9 months for standard treatments[49]. - The study at MD Anderson for recurrent GBM patients enrolled 89 patients, with 35 patients receiving 40 mg/m²/day and 54 patients receiving 30 mg/m²/day[51]. - The GBM AGILE Study employs a cost-efficient, adaptive design, allowing for simultaneous evaluation of multiple therapies under a master protocol[43]. - VAL-083 is being studied as a potential replacement for standard-of-care chemoradiation with temozolomide in newly-diagnosed MGMT-unmethylated GBM patients[46]. - Clinical studies indicate that VAL-083 has no evidence of lung, liver, or kidney toxicity, supporting its safety profile over 15 years in the Chinese market[80]. - The planned Phase 3 study aims to enroll approximately 100-150 CMBC patients who have received prior radiation therapy and chemotherapy[141]. - A preliminary open-label study with 15 patients is planned to confirm the dose and study design before the Phase 3 clinical study[140]. Drug Efficacy and Safety - VAL-083 has shown increased median overall survival benefits compared to radiation alone, targeting MGMT-unmethylated GBM patients[28]. - The median overall survival (mOS) for efficacy evaluable patients receiving 30 mg/m²/day of VAL-083 was reported as 8.0 months, with a PFS of 10.0 months for 36 efficacy evaluable patients[60][61]. - Myelosuppression was the most common adverse event associated with VAL-083, occurring in both recurrent and newly-diagnosed treatment settings[59]. - The overall median survival for newly diagnosed GBM patients with best available treatments is less than 15 months, highlighting the urgent need for effective therapies[65]. - VAL-083 has demonstrated activity against MGMT-unmethylated GBM cells resistant to temozolomide, with high efficacy in p53 mutated NSCLC, ovarian cancer, and medulloblastoma cell lines[77]. - VAL-083 has shown superior efficacy compared to standard platinum-based therapies in both TKI-sensitive and TKI-resistant NSCLC models[85]. - REM-001 Therapy has shown a complete response in approximately 80% of evaluable tumor sites in CMBC patients, indicating promising efficacy[99]. - REM-001 Therapy demonstrated a 66% complete response rate and a 90% overall response rate in a Phase 1 study involving 27 cutaneous tumor lesions[128]. - In a Phase 1/2 clinical study for BCCNS, REM-001 Therapy showed a 91% overall response rate, with a 68% complete response rate and a 23% partial response rate[123]. Regulatory Approvals and Designations - The FDA granted orphan drug designation for VAL-083 for the treatment of both ovarian cancer and gliomas, including GBM[33]. - The FDA has granted Fast Track designation for VAL-083 in recurrent GBM, which may expedite the review process and increase communication frequency with the FDA[62][63]. - The FDA granted orphan drug designation for REM-001's active ingredient, tin ethyl etiopurpurin, for the treatment of Basal Cell Carcinoma Nevus Syndrome (BCCNS) on January 16, 2018[108]. - The FDA grants five years of data exclusivity for a new chemical entity, which REM-001 is expected to qualify for if approved[142]. - Orphan drug designation can provide exclusivity for 7 years in the U.S. and 10 years in the E.U. for drugs treating rare diseases, but does not shorten the review process[196]. Market Potential and Competition - VAL-083 is projected to generate over $1.0 billion in sales for glioblastoma multiforme by 2027, over $6.0 billion for ovarian cancer by 2028, and over $22.0 billion for non-small cell lung cancer by 2027[91]. - The estimated market opportunity for the treatment of CMBC is approximately $500 million[121]. - The oncology market is highly competitive, with major pharmaceutical and biotechnology companies actively developing products for cancer treatment, including VAL-083 and REM-001[205]. - The company faces competition from numerous firms in oncology, including those with approved products like Merck's Temodar and Genentech's Avastin[208]. Intellectual Property and Manufacturing - The company has filed patent applications related to VAL-083, including improvements to manufacturing processes and treatment regimens[160]. - The company has acquired intellectual property for REM-001, including scientific and regulatory data, through an asset purchase agreement[181]. - The company has pending national phase applications for various patents in multiple countries, indicating ongoing efforts to expand its market presence[167][170][171][172][173]. - The protection of intellectual property rights in China is relatively weak, which may impact revenue generation from VAL-083 in that market[179]. - The current manufacturing process for VAL-083 involves fewer than five synthetic steps, with improvements made to the original process established by the NCI[143]. - The manufacturing process for REM-001 has been established for commercial scale production, with stability testing currently underway for two API lots[148]. - A strategic collaboration with Guangxi Wuzhou Pharmaceutical Company has been established, which is the only manufacturer licensed by the CFDA to produce VAL-083 for the China market[149]. - The company has engaged third-party contract manufacturers to meet FDA standards, with drug supply now manufactured under full cGMP conditions for future clinical studies[146]. Regulatory Compliance and Challenges - Regulatory approval is required for all major markets, necessitating substantial resources for compliance with testing, manufacturing, and marketing regulations[183][185]. - The approval process for drug manufacturing facilities is stringent, requiring inspections and compliance with good manufacturing practices[192]. - Regulatory compliance requires significant financial resources and time, with ongoing inspections and potential penalties for non-compliance[197]. - The company must navigate complex healthcare regulations, including the Anti-Kickback Statute and false claims laws, which could impose civil and criminal penalties[201]. - The company is aware of the potential for policy changes that could impact study sizes, timelines, and expenditures for drug approvals[195].